Stromal cells in tumor microenvironment and breast cancer

Cancer and Metastasis Reviews

Volumn 32, Issue 1-2, 2013, Pages 303-315

  Mao, Yan ^a   Keller, Evan T ^b   Garfield, David H ^a,c   Shen, Kunwei ^a   Wang, Jianhua ^d  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast cancer; Cancer associated fibroblasts (CAFs); Stromal cells; Tumor microenvironment

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALVASCULIN; CAVEOLIN 1; CELECOXIB; CHLOROQUINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN G2; DENOSUMAB; FIBRONECTIN; GELATINASE A; GELATINASE B; INTERLEUKIN 6; METFORMIN; PACLITAXEL; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLX 3397; PROTEIN KINASE B; PROTEIN P16; PROTEIN P21; ROFECOXIB; SMOOTH MUSCLE ACTIN; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIMENTIN; XAV 939;

ADIPOCYTE; ANGIOGENESIS; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; COLON CANCER; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; GENE EXPRESSION; HUMAN; INTRADUCTAL CARCINOMA; LUNG CANCER; LYMPHOMA; MACROPHAGE; MELANOMA; METASTASIS; NONHUMAN; OVARY CANCER; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STEM CELL; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR MICROENVIRONMENT; WOUND HEALING;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; FIBROBLASTS; HUMANS; NEOPLASM STAGING; PROGNOSIS; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84878114531     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9415-3     Document Type: Review

References (138)

1. Siegel, R., et al. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62(1), 10-29.
2. Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews, 8(2), 98-101.
3. Kalluri, R., et al. (2006). Fibroblasts in cancer. Nature Reviews. Cancer, 6(5), 392-401.
4. Ostman, A., et al. (2009). Cancer-associated fibroblasts and tumor growth - bystanders turning into key players. Current Opinion in Genetics and Development, 19(1), 67-73.
5. Loeffler, M., et al. (2006). Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. The Journal of Clinical Investigation, 116(7), 1955-1962.
6. Gabbiani, G., et al. (1971). Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia, 27(5), 549-550.
7. Dvorak, H. F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine, 315(26), 1650-1659.
8. Kojima, Y., et al. (2010). Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 107(46), 20009-20014.
9. Moskovits, N., et al. (2006). p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Research, 66(22), 10671-10676.
10. Aboussekhra, A. (2011). Role of cancer-associated fibroblasts in breast cancer development and prognosis. International Journal of Developmental Biology, 55(7-9), 841-849.
11. Kiaris, H., et al. (2005). Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Research, 65(5), 1627-1630.
12. Trimis, G., et al. (2008). Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors. Human Molecular Genetics, 17(22), 3596-3600.
13. Trimboli, A. J., et al. (2009). Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature, 461(7267), 1084-1091.
14. Trimmer, C., et al. (2011). Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Cancer Biology & Therapy, 11(4), 383-394.
15. Hill, R., et al. (2005). Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell, 123(6), 1001-1011.
16. Spaeth, E. L., et al. (2009). Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One, 4(4), e4992.
17. Jotzu, C., et al. (2010). Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor-derived factors. Analytical Cellular Pathology (Amsterdam), 33(2), 61-79.
18. Zeisberg, E. M., et al. (2007). Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Research, 67(21), 10123-10128.
19. Garin-Chesa, P., et al. (1990). Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proceedings of the National Academy of Sciences of the United States of America, 87(18), 7235-7239.
20. Erez, N., et al. (2010). Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell, 17(2), 135-147.
21. Mercier, I., et al. (2008). Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biology & Therapy, 7(8), 1212-1225.
22. Sugimoto, H., et al. (2006). Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biology & Therapy, 5(12), 1640-1646.
23. Perou, C. M., et al. (2000). Molecular portraits of human breast tumours. Nature, 406(6797), 747-752.
24. Haque, R., et al. (2012). PS1-05: disparities in breast cancer survival by molecular subtype and race/ethnicity. Clinical Medicine & Research, 10(3), 145.
25. Onitilo, A. A., et al. (2009). Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clinical Medicine & Research, 7(1-2), 4-13.
26. Martinez-Outschoorn, U. E., et al. (2010). Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle, 9(12), 2423-2433.
27. Lohr, M., et al. (2001). Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Research, 61(2), 550-555.
28. Bronzert, D. A., et al. (1987). Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America, 84(16), 5763-5767.
29. Shao, Z. M., et al. (2000). Human breast carcinoma desmoplasia is PDGF initiated. Oncogene, 19(38), 4337-4345.
30. Strutz, F., et al. (2000). Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney International, 57(4), 1521-1538.
31. Giannoni, E., et al. (2010). Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Research, 70(17), 6945-6956.
32. Hugo, H. J., et al. (2012). Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment. Cancer Microenvironment. doi: 10.1007/s12307-012-0098-7
33. Koleske, A. J., et al. (1995). Reduction of caveolin and caveolae in oncogenically transformed cells. Proceedings of the National Academy of Sciences of the United States of America, 92(5), 1381-1385.
34. Martinez-Outschoorn, U. E., et al. (2010). Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle, 9(16), 3256-3276.
35. Al-Ansari, M. M., et al. (2012). p16(INK4A) represses the paracrine tumor-promoting effects of breast stromal fibroblasts. Oncogene. doi: 10.1038/onc.2012.270
36. Serrano, M., et al. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366(6456), 704-707.
37. Ohtani, N., et al. (2004). The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. The Journal of Medical Investigation, 51(3-4), 146-153.
38. Matros, E., et al. (2005). BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Research and Treatment, 91(2), 179-186.
39. Hasebe, T., et al. (2001). Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Modern Pathology, 14(4), 325-337.
40. Orimo, A., et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121(3), 335-348.
41. Saito, R. A., et al. (2010). Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Research, 70(7), 2644-2654.
42. Zhang, C., et al. (2009). Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clinical Cancer Research, 15(12), 4017-4027.
43. Shekhar, M. P., et al. (2001). Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Research, 61(4), 1320-1326.
44. Sadlonova, A., et al. (2005). Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Research, 7(1), R46-R59.
45. Adams, E. F., et al. (1988). Effects of human breast fibroblasts on growth and 17 beta-estradiol dehydrogenase activity of MCF-7 cells in culture. Breast Cancer Research and Treatment, 11(2), 165-172.
46. Stuelten, C. H., et al. (2010). Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One, 5(3), e9832.
47. Hu, M., et al. (2009). Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proceedings of the National Academy of Sciences of the United States of America, 106(9), 3372-3377.
48. Hu, M., et al. (2008). Regulation of in situ to invasive breast carcinoma transition. Cancer Cell, 13(5), 394-406.
49. Tsuyada, A., et al. (2012). CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Research, 72(11), 2768-2779.
50. Qian, B. Z., et al. (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 475(7355), 222-225.
51. Tan, W., et al. (2011). Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature, 470(7335), 548-553.
52. Rossi, D., et al. (2000). The biology of chemokines and their receptors. Annual Review of Immunology, 18, 217-242.
53. Roodman, G. D. (2004). Mechanisms of bone metastasis. The New England Journal of Medicine, 350(16), 1655-1664.
54. Azim, H. A., et al. (2012). Bone metastasis in breast cancer: the story of RANK-ligand. Journal of the Egyptian National Cancer Institute, 24(3), 107-114.
55. Chen, J., et al. (2011). CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell, 19(4), 541-555.
56. Campbell, I., et al. (2009). Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Research, 69(17), 6765-6768. discussion 6769.
57. Hu, M., et al. (2005). Distinct epigenetic changes in the stromal cells of breast cancers. Nature Genetics, 37(8), 899-905.
58. Allinen, M., et al. (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 6(1), 17-32.
59. Enkelmann, A., et al. (2011). Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer. Journal of Cancer Research and Clinical Oncology, 137(5), 751-759.
60. Fiegl, H., et al. (2006). Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Research, 66(1), 29-33.
61. Jiang, L., et al. (2008). Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Research, 68(23), 9900-9908.
62. Yu, J., et al. (2012). Unlike pancreatic cancer cells pancreatic cancer associated fibroblasts display minimal gene induction after 5-aza-2′- deoxycytidine. PLoS One, 7(9), e43456.
63. Robinson, C. M., et al. (2012). Hypoxia-induced DNA hypermethylation in human pulmonary fibroblasts is associated with thy-1 promoter methylation and the development of a pro-fibrotic phenotype. Respiratory Research, 13(1), 74.
64. Knower, K. C., et al. (2010). Epigenetic mechanisms regulating CYP19 transcription in human breast adipose fibroblasts. Molecular and Cellular Endocrinology, 321(2), 123-130.
65. Tyan, S. W., et al. (2012). Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change. PLoS One, 7(4), e35128.
66. Gangaraju, V. K., et al. (2009). MicroRNAs: key regulators of stem cells. Nature Reviews Molecular Cell Biology, 10(2), 116-125.
67. Fazi, F., et al. (2008). MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovascular Research, 79(4), 553-561.
68. Leung, A. K., et al. (2006). Function and localization of microRNAs in mammalian cells. Cold Spring Harbor Symposia on Quantitative Biology, 71, 29-38.
69. Tiscornia, G., et al. (2010). MicroRNAs in embryonic stem cell function and fate. Genes & Development, 24(24), 2732-2741.
70. Davis-Dusenbery, B. N., et al. (2010). MicroRNA in cancer: the involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer, 1(11), 1100-1114.
71. Farazi, T. A., et al. (2011). MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Research, 71(13), 4443-4453.
72. Iliopoulos, D., et al. (2009). An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell, 139(4), 693-706.
73. Iliopoulos, D., et al. (2010). STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Molecular Cell, 39(4), 493-506.
74. Iorio, M. V., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Research, 65(16), 7065-7070.
75. Jazbutyte, V., et al. (2010). MicroRNA-21: from cancer to cardiovascular disease. Current Drug Targets, 11(8), 926-935.
76. Qian, B., et al. (2009). High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Research and Treatment, 117(1), 131-140.
77. Aprelikova, O., et al. (2012). Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene. doi: 10.1038/onc.2012.351
78. Aprelikova, O., et al. (2010). The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle, 9(21), 4387-4398.
79. Musumeci, M., et al. (2010). Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene, 30(41), 4231-4242.
80. Martinez-Outschoorn, U. E., et al. (2011). Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biology & Therapy, 12(10), 924-938.
81. Sun, Y., et al. (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nature Medicine. doi: 10.1038/nm.2890
82. Tchou, J., et al. (2012). Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. Advances in Pharmacology, 65, 45-61.
83. Davies, C., et al. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771-784.
84. Shekhar, M. P., et al. (2007). Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. American Journal of Pathology, 170(5), 1546-1560.
85. Pontiggia, O., et al. (2012). The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin. Breast Cancer Research and Treatment, 133(2), 459-471.
86. Mueller, K. L., et al. (2012). Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Research, 14(4), R104.
87. Johansson, A. C., et al. (2012). Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells. Molecular Cancer Research, 10(9), 1158-1168.
88. Dittmer, A., et al. (2011). Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors. International Journal of Oncology, 39(3), 689-696.
89. Capparelli, C., et al. (2012). CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle, 11(19).
90. Bergamaschi, A., et al. (2008). Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. The Journal of Pathology, 214(3), 357-367.
91. Finak, G., et al. (2008). Stromal gene expression predicts clinical outcome in breast cancer. Nature Medicine, 14(5), 518-527.
92. Sloan, E. K., et al. (2009). Stromal cell expression of caveolin-1 predicts outcome in breast cancer. American Journal of Pathology, 174(6), 2035-2043.
93. Pavlides, S., et al. (2009). The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle, 8(23), 3984-4001.
94. Farmer, P., et al. (2009). A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine, 15(1), 68-74.
95. Ahn, S., et al. (2012). The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biology, 33, 1573-1580.
96. Martinet, L., et al. (2011). Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Research, 71(17), 5678-5687.
97. DeNardo, D. G., et al. (2011). Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery, 1(1), 54-67.
98. Laoui, D., et al. (2011). Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. International Journal of Developmental Biology, 55(7-9), 861-867.
99. Lee, A. H., et al. (1997). Angiogenesis and inflammation in invasive carcinoma of the breast. Journal of Clinical Pathology, 50(8), 669-673.
100. Campbell, M. J., et al. (2011). Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Research and Treatment, 128(3), 703-711.
101. Leek, R. D., et al. (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Research, 56(20), 4625-4629.
102. Lewis, C. E., et al. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Research, 66(2), 605-612.
103. Lewis, J. S., et al. (2000). Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. The Journal of Pathology, 192(2), 150-158.
104. Dirkx, A. E., et al. (2006). Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Journal of Leukocyte Biology, 80(6), 1183-1196.
105. Roland, C. L., et al. (2009). Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Molecular Cancer Therapeutics, 8(7), 1761-1771.
106. Melani, C., et al. (2007). Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Research, 67(23), 11438-11446.
107. Lin, E. Y., et al. (2001). Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. The Journal of Experimental Medicine, 193(6), 727-740.
108. Oosterling, S. J., et al. (2005). Macrophages direct tumour histology and clinical outcome in a colon cancer model. The Journal of Pathology, 207(2), 147-155.
109. Mukhtar, R. A., et al. (2011). Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Review of Molecular Diagnostics, 11(1), 91-100.
110. Nilsson, S., et al. (2012). Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. PLoS One, 7(4), e36051.
111. Yang, M., et al. (2011). Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Molecular Cancer, 10, 117.
112. Hiraoka, K., et al. (2008). Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Science, 99(8), 1595-1602.
113. Gazzaniga, S., et al. (2007). Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. The Journal of Investigative Dermatology, 127(8), 2031-2041.
114. Zeisberger, S. M., et al. (2006). Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. British Journal of Cancer, 95(3), 272-281.
115. Zhang, W., et al. (2010). Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clinical Cancer Research, 16(13), 3420-3430.
116. Veltman, J. D., et al. (2010). Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. British Journal of Cancer, 103(5), 629-641.
117. Luckman, S. P., et al. (1998). Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. Journal of Bone and Mineral Research, 13(11), 1668-1678.
118. Cecchini, M. G., et al. (1987). Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. Journal of Bone and Mineral Research, 2(2), 135-142.
119. Coscia, M., et al. (2010). Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 14(12), 2803-2815.
120. Man, Y. G., et al. (2004). The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the "protease-centered" hypothesis. Experimental Cell Research, 301(2), 103-118.
121. Knutson, K. L., et al. (2006). IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. Journal of Immunology, 177(1), 84-91.
122. + lymphocytes predict clinical outcome in breast cancer. Journal of Clinical Oncology, 29(15), 1949-1955.
123. Ruffell, B., et al. (2012). Leukocyte composition of human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 109(8), 2796-2801.
124. Acharyya, S., et al. (2011). A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell, 150(1), 165-178.
125. Iyengar, P., et al. (2005). Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. The Journal of Clinical Investigation, 115(5), 1163-1176.
126. Iyengar, P., et al. (2003). Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene, 22(41), 6408-6423.
127. Finley, D. S., et al. (2009). Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. Journal of Urology, 182(4), 1621-1627.
128. Yu, J. M., et al. (2008). Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells and Development, 17(3), 463-473.
129. Walter, M., et al. (2009). Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene, 28(30), 2745-2755.
130. Welte, G., et al. (2012). Interleukin-8 derived from local tissue-resident stromal cells promotes tumor cell invasion. Molecular Carcinogenesis, 51, 861-868.
131. Pinilla, S., et al. (2009). Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Letters, 284(1), 80-85.
132. Devarajan, E., et al. (2011). Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells. International Journal of Cancer, 131(5), 1023-1031.
133. Muehlberg, F. L., et al. (2009). Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis, 30(4), 589-597.
134. Bochet, L., et al. (2011). Cancer-associated adipocytes promotes breast tumor radioresistance. Biochemical and Biophysical Research Communications, 411(1), 102-106.
135. Ligibel, J. (2011). Obesity and breast cancer. Oncology (Williston Park, N.Y.), 25(11), 994-1000.
136. Dirat, B., et al. (2010). Unraveling the obesity and breast cancer links: a role for cancer-associated adipocytes? Endocrine Development, 19, 45-52.
137. Harris, R. E., et al. (2009). Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology, 17(2), 55-67.
138. Dougall, W. C., et al. (2012). Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clinical Cancer Research, 18(2), 326-335.